Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 1.00 |
| ▸ | CNR1 | P21554 | 6/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30544878 | 1.00 | CNR2 (1.00) | CNR2CNR1TDP1 | |
| SCHEMBL14746942 | 0.94 | CNR2 (0.88) | CNR2CNR1TDP1 | |
| SCHEMBL14746864 | 0.93 | CNR2 (0.86) | CNR2CNR1TDP1 | |
| SCHEMBL14746878 | 0.90 | CNR2 (0.82) | CNR2CNR1TDP1 | |
| SCHEMBL14746932 | 0.90 | CNR2 (0.81) | CNR2CNR1TDP1 | |
| SCHEMBL14742094 | 0.89 | CNR2 (0.81) | CNR2CNR1TDP1 | |
| SCHEMBL14746913 | 0.89 | CNR2 (0.81) | CNR2CNR1TDP1 | |
| SCHEMBL16243955 | 0.89 | CNR2 (0.81) | CNR2CNR1TDP1 | |
| SCHEMBL14746929 | 0.89 | CNR2 (0.81) | CNR2CNR1TDP1 | |
| SCHEMBL14746853 | 0.89 | CNR2 (0.80) | CNR2CNR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170014355-A1 | CANNABINOID RECEPTOR TREATMENTS | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2017-01-19 | — | — | US | claimed |
| US-9289421-B2 | Methods and compositions for reducing serum levels of immunoglobulin E (IgE) | UNIVERSITY OF SOUTH FLORIDA (US) | 2016-03-22 | — | — | US | claimed |
| US-20140350052-A1 | Methods and Compositions for Reducing Serum Levels of Immunoglobulin E (IGE) | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-11-27 | — | — | US | claimed |
| WO-2013033155-A1 | METHODS AND COMPOSITIONS FOR REDUCING SERUM LEVELS OF IMMUNOGLOBULIN E (IGE) | UNIVERSITY OF SOUTH FLORIA (US) | 2013-03-07 | — | — | WO | claimed |
| WO-2013025984-A2 | CANNABINOID RECEPTOR TREATMENTS | TEMPLE UNIVERSITY (US) | 2013-02-21 | — | — | WO | claimed |
| US-20230255970-A1 | COMPOSITIONS AND METHODS FOR TREATING PROLIFERATIVE DISEASES | THE BROAD INSTITUTE, INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-20180200225-A1 | HYDRAZONE MODULATORS OF CANNABINOID RECEPTORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2018-07-19 | — | — | US | disclosed |
| US-9855225-B2 | Cannabinoid receptor treatments | TEMPLE UNIVERSITY OFFICE OF TECHNOLOGY TRANSFER (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170355959-A1 | METHODS FOR MOBILISING POPULATIONS OF STEM CELLS | IMPERIAL INNOVATIONS LTD (GB) | 2017-12-14 | — | — | US | disclosed |
| US-20170231953-A1 | HYDRAZONE MODULATORS OF CANNABINOID RECEPTORS | CLEVELAND CLINIC FOUND (US) | 2017-08-17 | — | — | US | disclosed |
| US-9656957-B2 | Hydrazone modulators of cannabinoid receptors | THE CLEVELAND CLINIC FOUNDATION (US) | 2017-05-23 | — | — | US | disclosed |
| US-20170014355-A1 | CANNABINOID RECEPTOR TREATMENTS | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2017-01-19 | — | — | US | disclosed |
| WO-2013025984-A2 | CANNABINOID RECEPTOR TREATMENTS | TEMPLE UNIVERSITY (US) | 2013-02-21 | — | — | WO | disclosed |
| US-8309595-B2 | Hydrazone modulators of cannabinoid receptors | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-11-13 | — | — | US | disclosed |
| EP-2223913-A1 | Tricyclic pyrazole derivatives and microemulsions thereof as CB1- and/or CB2-inhibitors | Neuroscienze Pharmaness S.C. A R.L. (IT) | 2010-09-01 | — | — | EP | disclosed |
| US-20100216785-A1 | PHARMACEUTICAL COMPOSITIONS | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2010-08-26 | — | — | US | disclosed |
| US-20100216785-A1 | PHARMACEUTICAL COMPOSITIONS | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2010-08-26 | — | — | US | disclosed |
| US-20100216785-A1 | PHARMACEUTICAL COMPOSITIONS | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2010-08-26 | — | — | US | disclosed |
| US-20100197755-A1 | HYDRAZONE MODULATORS OF CANNABINOID RECEPTORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2010-08-05 | — | — | US | disclosed |
| WO-2009012227-A1 | HYDRAZONE MODULATORS OF CANNABINOID RECEPTORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170014355-A1 | CANNABINOID RECEPTOR TREATMENTS | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885TDP1 4764/4885 |
| US-20170231953-A1 | HYDRAZONE MODULATORS OF CANNABINOID RECEPTORS | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885TDP1 4684/4885 |
| US-20100197755-A1 | HYDRAZONE MODULATORS OF CANNABINOID RECEPTORS | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885TDP1 4684/4885 |
| US-20100216785-A1 | PHARMACEUTICAL COMPOSITIONS | CNR2, CNR1, SGMS2 | CNR2 1/4885CNR1 2/4885TDP1 4784/4885 |
| US-20230255970-A1 | COMPOSITIONS AND METHODS FOR TREATING PROLIFERATIVE DISEASES | YAP1, RELA, NFKBIA | CNR2 3876/4885CNR1 3794/4885TDP1 1896/4885 |
| US-20180200225-A1 | HYDRAZONE MODULATORS OF CANNABINOID RECEPTORS | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885TDP1 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.